Baxter International Selects Georgia for $1 Billion Bio-Pharmaceutical Manufacturing Investment
ATLANTA, GA - Gov. Nathan Deal today announced that Baxter International will locate a new bio-pharmaceutical manufacturing facility near Interstate 20 east of Atlanta as well as plasma centers throughout Georgia that will employ approximately 1,500 people across the state with the potential for hundreds more. Total investment by the company will exceed $1 billion. “Baxter’s decision to come to Georgia marks a new era in the growth of our biosciences industry and will have far-reaching impact on our economy,” said Deal. “We are honored to welcome this flagship company to Georgia and...
Read MoreBristol-Myers Squibb to Acquire Inhibitex
NEW YORK & PRINCETON, N.J. & ATLANTA–Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex’s shareholders tender their shares in...
Read MoreGeorgia Bio Deals of the Year Spotlight Financings, Acquisitions, Emerging Stars
ATLANTA–Georgia Bio announced its 2012 Deals of the Year for pharmaceutical, biopharmaceutical and medical device companies in four categories – public and private financings, fast growing companies, acquisitions and SBIR grants – reflecting a broad range of activity. The annual Deal of the Year awards recognize transactions by life sciences companies in Georgia that are significant to state’s industry development. The recipients will receive their awards at the Georgia Bio Annual Awards Dinner January 26, 6 pm to 9 pm, at Atlanta’s Fox Theater. Here is a link to...
Read MoreClearside Biomedical Launched with Pipeline and Technology Focused on Drugs Delivered to the Back of the Eye
ATLANTA, GA and DURHAM, NC - Ophthalmic startup Clearside Biomedical and Hatteras Venture Partners announce today that they have launched the company with a $4,000,000 Series A venture financing to fund the initial development of Clearside Biomedical’s ocular microinjection platform and initial clinical testing of Clearside Biomedical’s lead product for Macular Edema and Retinal Vein Occlusion. Clearside Biomedical’s proprietary ocular microinjection platform has been designed to non-surgically deliver drugs to an area of the eye referred to as the suprachoroidal space which...
Read MoreSanford-Burnham Scientist Receives Research Grant from Novo Nordisk
ORLANDO, Fla., December 15, 2011 – Layton Smith, Ph.D., assistant professor and director of drug discovery at Sanford-Burnham Medical Research Institute’s Florida campus, has been awarded a Novo Nordisk Diabetes Innovation Award, valued at $477,500 over two years. The grant will further his research into a novel protein with the potential to improve the understanding of diabetes and further the development of new treatments. Novo Nordisk is an international healthcare company based in Denmark that is recognized as a world leader in diabetes treatment. The Novo Nordisk Diabetes Innovation...
Read MoreOxygen raises $7.5M through share issue
Morrisville, NC – Morrisville’s Oxygen Biotherapeutics will sell new shares of the company to an institutional investor, raising up to $7.5 million in the process.Oxygen (Nasdaq: OXBT) has dealt with some corporate issues lately. The company terminated Chris Stern as CEO for alleged inaccuracies on his resumé, was warned by Nasdaq because its audit committee was out of compliance, and removed its shares from the Swiss Exchange. But interim CEO Michael B. Jebsen is looking forward, not back. “The ($7.5 million in) proceeds, along with our recent initiatives to reduce our cash burn...
Read More
Follow Us!